Inclusion Criteria:  Patients must be ≥ 18 years of age Patients must have measurable disease per disease-specific response criteria Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, or Lugano Classification of Lymphoma response criteria) Patients with transformed lymphoma are eligible for the study with the exception of those who have Richter's transformation, prolymphocytic leukemia, or blastoid lymphoma prior to planned start of study drug Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ and bone marrow function, in the absence of growth factors Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol  Inclusion Criteria for Patients in Phase 1a:  Have histologically confirmed R/R CLL, SLL, WM, MCL, and MZL, FL(grade 1 - 3b), and DLBCL (High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements and high-grade B-cell lymphoma NOS) Received at least 2 prior systemic therapies (or 1 prior therapy for patients with WM) and have no other therapies known to provide clinical benefit Must require systemic therapy  Inclusion Criteria for Patients in Phase 1b:  Must have one of the following histologically documented R/R B-cell malignancies:  CLL/SLL with no BTK C481 mutation whose disease has failed treatment with a BTKi; BTK C481 mutation-positive CLL/SLL whose disease has failed treatment with a BTKi; MCL or MZL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen or WM whose disease has failed treatment with BTKi FL (grade 1 - 3b) whose disease has failed treatment with anti-CD20 mAb-based regimen;  DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and an anthracycline (either progressed post stem cell transplant or transplant-ineligible)  DLBCL histologies include high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements and high-grade B-cell lymphoma NOS  Exclusion Criteria:  History of CNS lymphoma/leukemia in remission for less than 2 years Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia History of known/suspected other autoimmune disease (exception(s): patients with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.) Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug Bleeding diathesis, or other known risk for acute blood loss Patients requiring ongoing treatment with chronic, therapeutic anticoagulation with warfarin or patients treated with dual anti-platelet therapy and vitamin K antagonists Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation) Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).  Active known second malignancy with the exception of any of the following:  Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for ≥ 2 years; Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 ng/mL; or Any other cancer from which the patient has been disease-free for ≥ 2 years Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 > 350/mm3 and undetectable viral load) are eligible. Current active liver disease from any cause Active viral reactivation (e.g., CMV or EBV) Use of systemic corticosteroids (> 20 mg/day prednisone or equivalent) Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug Patient is taking strong or moderate cytochrome P450 3A (CYP3A) inducers or inhibitors or inhibitors of P-glycoprotein